Status:
UNKNOWN
Tw HER2 Positive Breast Cancer Productivity & Utility Study
Lead Sponsor:
Taiwan Epidemiology Association
Conditions:
HER2-positive Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Breast cancer ranks top 4 Taiwan mortality cause in 2016 and the incidence rate has been increasing. Since advances in screening and treatment over last decades, disease-free survival in HER2 positive...
Detailed Description
Breast cancer ranks top 4 Taiwan mortality cause in 2016 and the incidence rate has been increasing. Since advances in screening and treatment over last decades, disease-free survival in HER2 positive...
Eligibility Criteria
Inclusion
- Aged 18 years or over;
- Diagnosed with early stage or metastatic (Stage IV) HER2-positive breast cancer (confirmed by the study site physician). \[HER2-positive is defined as IHC3+ and/or ISH≥2.0\]
- eBC patients should have received at least 2 cycles of adjuvant anti-cancer therapy following surgery at time of interview; metastasis breast cancer (mBC) patients should have received at least 1 cycle of treatment for their metastatic disease at time of interview.
- Able to provide written, informed consent.
Exclusion
- Patients with ECOG performance status (PS) ≥3
- Unwilling or unable to provide written, informed consent
- Unable to complete written quality of life questionnaires
Key Trial Info
Start Date :
December 24 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04011085
Start Date
December 24 2018
End Date
December 31 2019
Last Update
July 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University hospital
Taipei, Taiwan, 100